# A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants

> **NCT05436912** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 36 (actual)

## Conditions studied

- Healthy
- Hepatic Impairment

## Interventions

- **DRUG:** Selpercatinib

## Key facts

- **NCT ID:** NCT05436912
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-10
- **Primary completion:** 2019-10-04
- **Final completion:** 2019-10-30
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05436912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05436912, "A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05436912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*